CN Patent

CN111777620A — 酪氨酸激酶抑制剂的新用途

Assigned to Shandong Xuanzhu Pharma Co Ltd · Expires 2020-10-16 · 6y expired

What this patent protects

本发明属于医药技术领域，具体涉及式(I)所示的化合物、其立体异构体、其药学上可接受的盐及其晶型的新用途，R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、L、n如说明书中所定义；本发明具体涉及这些化合物、包含这些化合物的药物制剂及药物组合物在制备用于治疗携带EGFR 20位外显子插入突变的肿瘤患者的药物中的用途。

USPTO Abstract

本发明属于医药技术领域，具体涉及式(I)所示的化合物、其立体异构体、其药学上可接受的盐及其晶型的新用途，R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、L、n如说明书中所定义；本发明具体涉及这些化合物、包含这些化合物的药物制剂及药物组合物在制备用于治疗携带EGFR 20位外显子插入突变的肿瘤患者的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN111777620A
Jurisdiction
CN
Classification
—
Expires
2020-10-16
Drug substance claim
No
Drug product claim
No
Assignee
Shandong Xuanzhu Pharma Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.